Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FEMY Femasys	$0.73 -5.9%	$0.89	$0.69 ▼ $1.80	$25.26M	-2.58	220,528 shs	326,799 shs
GUTS Fractyl Health	$0.98 +0.7%	$1.74	$0.83 ▼ $3.72	$47.85M	1.66	1.08 million shs	1.46 million shs
ICAD icad	$3.87	$3.82	$1.19 ▼ $4.02	$106.31M	1.37	426,282 shs	N/A
OBIO Orchestra BioMed	$2.72 +7.9%	$3.01	$2.37 ▼ $7.04	$97.38M	0.62	352,485 shs	526,555 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FEMY Femasys	-13.16%	-4.07%	-16.15%	-29.51%	-16.63%
GUTS Fractyl Health	+1.62%	-47.47%	-35.72%	-44.80%	-45.11%
ICAD icad	0.00%	0.00%	+3.48%	-1.53%	+204.72%
OBIO Orchestra BioMed	-7.01%	-5.97%	-13.70%	-14.29%	-59.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FEMY Femasys	3.4441 of 5 stars	3.5	5.0	2.4	2.5	0.6
GUTS Fractyl Health	2.4912 of 5 stars	3.5	3.0	3.0	1.7	0.0
ICAD icad	0.58 of 5 stars	0.0	5.0	1.2	0.8	0.0
OBIO Orchestra BioMed	2.8623 of 5 stars	3.6	3.0	3.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FEMY Femasys	3.00	Buy	$7.33	904.57% Upside
GUTS Fractyl Health	3.00	Buy	$11.00	1,018.00% Upside
ICAD icad	2.00	Hold	N/A	N/A
OBIO Orchestra BioMed	3.20	Buy	$14.00	414.71% Upside

Current Analyst Ratings Breakdown

Latest FEMY, OBIO, ICAD, and GUTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	FEMY Femasys	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
8/7/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/25/2025	FEMY Femasys	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/11/2025	FEMY Femasys	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
5/13/2025	FEMY Femasys	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $6.00
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FEMY Femasys	$1.63M	14.59	N/A	N/A	$0.05 per share	14.60
GUTS Fractyl Health	$90K	535.46	N/A	N/A	$0.59 per share	1.67
ICAD icad	$19.61M	5.42	N/A	N/A	$1.08 per share	3.58
OBIO Orchestra BioMed	$2.64M	39.81	N/A	N/A	$0.87 per share	3.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FEMY Femasys	-$18.82M	-$0.86	N/A	N/A	N/A	-1,113.72%	-713.74%	-152.60%	8/14/2025 (Estimated)
GUTS Fractyl Health	-$68.69M	-$1.85	0.00	N/A	N/A	-73,864.52%	-228.66%	-76.74%	8/12/2025 (Estimated)
ICAD icad	-$5.62M	-$0.19	N/A	∞	N/A	-26.63%	-15.03%	-11.77%	8/12/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A

Latest FEMY, OBIO, ICAD, and GUTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GUTS Fractyl Health	-$0.37	-$0.53	-$0.16	-$0.57	N/A	N/A
8/12/2025	Q2 2025	ICAD icad	-$0.0550	N/A	N/A	N/A	$4.81 million	N/A
8/11/2025	Q2 2025	OBIO Orchestra BioMed	-$0.51	-$0.50	+$0.01	-$0.50	$0.78 million	$0.84 million
8/8/2025	Q2 2025	FEMY Femasys	-$0.18	-$0.16	+$0.02	-$0.16	$0.80 million	$0.41 million
5/13/2025	Q1 2025	GUTS Fractyl Health	-$0.49	-$0.49	N/A	-$0.49	N/A	N/A
5/13/2025	Q1 2025	ICAD icad	-$0.0625	-$0.02	+$0.0425	-$0.03	$4.54 million	$4.87 million
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FEMY Femasys	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	N/A	N/A	N/A	N/A	N/A
ICAD icad	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FEMY Femasys	0.03	0.89	0.54
GUTS Fractyl Health	4.61	2.50	2.50
ICAD icad	N/A	3.66	3.57
OBIO Orchestra BioMed	0.85	3.35	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FEMY Femasys	65.27%
GUTS Fractyl Health	N/A
ICAD icad	24.61%
OBIO Orchestra BioMed	53.20%

Insider Ownership

Company	Insider Ownership
FEMY Femasys	11.54%
GUTS Fractyl Health	27.00%
ICAD icad	10.29%
OBIO Orchestra BioMed	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FEMY Femasys	30	32.58 million	28.77 million	Not Optionable
GUTS Fractyl Health	102	48.98 million	35.75 million	N/A
ICAD icad	140	27.47 million	24.64 million	Optionable
OBIO Orchestra BioMed	4	38.64 million	35.51 million	Not Optionable

FEMY, OBIO, ICAD, and GUTS Headlines

Recent News About These Companies

Orchestra BioMed reports Q2 EPS (50c), consensus (51c)

August 12 at 4:01 PM | msn.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates

August 12 at 4:01 PM | zacks.com

Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

August 12 at 10:58 AM | finanznachrichten.de

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

August 12 at 8:14 AM | globenewswire.com

Brokerages Set Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Target Price at $14.00

August 9 at 2:25 AM | americanbankingnews.com

Orchestra BioMed rises as trial for antihypertensive drug expands

August 8, 2025 | msn.com

Orchestra BioMed's (OBIO) Buy Rating Reiterated at Chardan Capital

August 8, 2025 | marketbeat.com

FDA approves expansion to Orchestra BioMed pacemaker trial

August 8, 2025 | massdevice.com

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

August 8, 2025 | globenewswire.com

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of "Buy" by Analysts

August 6, 2025 | marketbeat.com

David P. Hochman Purchases 20,000 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Stock

August 5, 2025 | marketbeat.com

Orchestra BioMed (OBIO) Projected to Post Earnings on Monday

August 5, 2025 | marketbeat.com

Orchestra BioMed brings in $111M through Medtronic, Ligand deals

August 5, 2025 | massdevice.com

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

August 5, 2025 | globenewswire.com

Insider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Acquires 20,000 Shares of Stock

August 5, 2025 | insidertrades.com

Orchestra BioMed Secures $70 Million in Strategic Investments to Advance Cardiology Pipeline

August 3, 2025 | msn.com

Orchestra BioMed prices $40M offering, amends Medtronic deal

August 1, 2025 | massdevice.com

Orchestra BioMed Holdings, Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

August 1, 2025 | quiverquant.comQ

Orchestra BioMed Announces Pricing of $40 Million Public Offering

August 1, 2025 | globenewswire.com

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

July 31, 2025 | finance.yahoo.com

Orchestra BioMed Announces Proposed Public Offering

July 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY, OBIO, ICAD, and GUTS Company Descriptions

Femasys NASDAQ:FEMY

$0.73 -0.05 (-5.86%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 +0.06 (+7.53%)

As of 07:54 PM Eastern

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Fractyl Health NASDAQ:GUTS

$0.98 +0.01 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 0.00 (-0.40%)

As of 07:59 PM Eastern

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

icad NASDAQ:ICAD

$3.87 0.00 (0.00%)

As of 07/17/2025

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Orchestra BioMed NASDAQ:OBIO

$2.72 +0.20 (+7.94%)

Closing price 04:00 PM Eastern

Extended Trading

$2.73 +0.01 (+0.37%)

As of 07:42 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time